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Abstract: The role of rhinoviruses (RVs) in children with clinical syndromes not classically associated
with RV infections is not well understood. We analyzed a cohort of children ≤21 years old who were
PCR+ for RV at a large Pediatric Hospital from 2011 to 2013. Using univariate and multivariable
logistic regression, we analyzed the associations between demographic, clinical characteristics,
microbiology data, and clinical outcomes in children with compatible symptoms and incidental
RV detection. Of the 2473 children (inpatients and outpatients) with an RV+ PCR, 2382 (96%) had
compatible symptoms, and 91 (4%) did not. The overall median age was 14 months and 78% had
underlying comorbidities. No differences in RV viral loads were found according to the presence of
compatible symptoms, while in children with classic RV symptoms, RV viral loads were higher in
single RV infections versus RV viral co-infections. Bacterial co-infections were more common in RV
incidental detection (7.6%) than in children with compatible symptoms (1.9%, p < 0.001). The presence
of compatible symptoms independently increased the odds ratio (OR, 95% CI) of hospitalization 4.8
(3.1–7.4), prolonged hospital stays 1.9 (1.1–3.1), need for oxygen 12 (5.8–25.0) and pediatric intensive
care unit (PICU) admission 4.13 (2.0–8.2). Thus, despite comparable RV loads, disease severity was
significantly worse in children with compatible symptoms.
Keywords: rhinovirus; respiratory tract diseases; signs and symptoms; respiratory; infections; viral
load; children
1. Introduction
Human rhinoviruses (RVs) are the most common etiologic agents of acute respiratory
tract infections in children and adults. RVs are commonly associated with the common cold,
being responsible for over one-half of all upper respiratory tract infections (URTI) across
all age ranges [1]. More recently, RVs have also been implicated in lower respiratory tract
infections such as bronchitis, community-acquired pneumonia [1–7] bronchiolitis [1,4,8],
and asthma exacerbations [1,4].
In the last two decades, the implementation of sensitive molecular tools for the diagnosis
of RV infections has largely broadened the understanding of RV associated illnesses and has
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shown that RV can be detected in asymptomatic subjects [2,3,9–11]. In fact, rates of RV detection
in asymptomatic children are higher than in adults ranging from 15% to 50% [11–13]. In
addition, in the clinical setting, it is not uncommon to identify RV in combination with
other respiratory viruses or in patients presenting with clinical syndromes that appear
to be unrelated to classic RV infections, such as bone and joint infections or trauma. The
high rates of RV detection in subjects presenting without compatible symptoms or who are
completely asymptomatic have raised questions regarding the role of RV in certain clinical
scenarios. Previous studies have attempted to define the significance of RV viral loads in
asymptomatic subjects and to identify clinically relevant cut-off values for viral loads to
help attribute RV causality in symptomatic patients [10,13,14]. Nevertheless, the role of RV
detection in children with clinical syndromes not commonly associated with RV infections,
and whether RV viral loads differ from those of children with classic RV-associated illnesses
is not known.
The aim of the present study was to define demographic characteristics, clinical
presentations, RV viral loads, viral and bacterial co-infections, and clinical outcomes in a
convenience sample of children with RV-associated illnesses.
2. Materials and Methods
2.1. Study Design and Definitions
A retrospective cross-sectional study of a convenience sample of inpatients and outpa-
tients who were ≤21 years old and tested positive for RV by PCR in respiratory samples
obtained from 28 July 2011 to 31 December 2013 at Nationwide Children’s Hospital (NCH).
NCH is the only tertiary care Children’s Hospital in Columbus (Ohio), and it is affiliated
with The Ohio State University.
Patients were tested at the discretion of the attending physician, and PCR for seven
respiratory viruses (RV, respiratory syncytial virus (RSV), parainfluenza virus (PIV), in-
fluenza virus (IV) A and B, adenovirus (ADV), and human metapneumovirus (hMPV))
ordered as a panel. Respiratory samples were processed at NCH Microbiology Laboratory
following validated procedures. Respiratory samples tested included nasopharyngeal swab
samples, bronchoalveolar lavage (BAL), and endotracheal tube specimens. The RV reverse
transcription-PCR (RT-PCR) used targeted the 5´noncoding region (or 5´UTR) of RV as
described [15]. Semiquantitative RV viral loads were reported as CT values. CT value > 40
were considered negative. Molecular typing of RV was not performed.
For children that were evaluated for the same episode in the outpatient and inpatient
settings, only the hospitalization episode was analyzed. Similarly, for patients with multiple
RV-associated hospitalizations, only the first admission during the same respiratory season
was included. The seasonal pattern of RV infections was analyzed only in hospitalized
patients due to the lack of consistent data in outpatients. We excluded patients > 21 years
of age, those with no electronic health care records (EHR), or those who lacked complete
clinical data.
Children in whom RV was identified were classified into two groups according to their
clinical presentation—children with compatible symptoms (RV symptoms group) and those
presenting with conditions in whom RV was not thought to play a role in the clinical presenta-
tion (RV incidental group). A compatible clinical presentation was defined by the presence of
respiratory symptoms, fever, and/or gastrointestinal symptoms [1,16–18]. Children with RV
detection without any of these clinical manifestations were included in the RV incidental
group. Most of these children were tested as part of pre-screening procedures.
2.2. Data Collection
The following information was extracted from electronic health care records (HER),
deposited into an electronic secured database (REDCap), and manually reviewed by two
independent investigators. Briefly, we collected demographic and epidemiologic factors,
including the presence of comorbidities and diagnosis. Microbiology tests performed
included detection of other respiratory viruses in respiratory samples by PCR and bacterial
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cultures performed in blood, cerebrospinal fluid (CSF), urine, BAL, lower respiratory
samples, and cystic fibrosis (CF) upper respiratory samples. Parameters of disease-severity
were also analyzed and included the need for hospitalization, and in hospitalized patients,
duration of hospitalization, need for and duration of supplemental oxygen (nasal cannula,
non-invasive ventilation, or intubation), need for pediatric intensive care unit (PICU)
admission, and duration of PICU stay. These are standard parameters of disease severity
used in previous studies [19–21]. For analysis purposes, in children with more than one
respiratory-related diagnosis at presentation or in those with multiple comorbidities, the
most severe and relevant underlying disease was selected. The study was approved by the
NCH Institutional Review Board.
2.3. Statistical Analysis
Qualitative variables were expressed as frequency and percentages. Quantitative
variables were tested for normality and were reported as means and standard deviation
(SD) if they followed a normal distribution, or as medians and 25–75% interquartile ranges
(IQR) if data did not follow a normal distribution. For bivariate analysis, a chi-squared
test or two-tailed Fisher’s exact tests were used to compare proportions, and t-test or
Kruskal–Wallis tests for continuous data. We performed binary logistic regression to
study the relationships between clinical factors (covariates) and outcome variables (need
for hospitalization, PICU, length of stay, need for supplemental oxygen) and performed
a post-estimation analysis of the univariate logistic regression models generated, with
the estimation of the optimal cut- off values for those outcomes. Next, we performed
multivariable logistic regression and included covariates that were significant in bivariate
models or clinically relevant in relation to the clinical outcomes mentioned above. Two-
sided p-values < 0.05 were considered statistically significant. Statistical analyses were
performed using STATA 16.0. (StataCorp, College Station, TX, USA).
3. Results
3.1. Study Patients, Diagnoses, and Seasonality of RV Infections
From 28 July 2011 to 31 December 2013, 13,150 respiratory samples from children
evaluated in the inpatient and outpatient setting were analyzed by PCR at NCH Microbiol-
ogy Laboratory (Figure 1). Of those, 3583/13150 (27%) children tested positive for RV. We
excluded duplicate samples collected during the same episode, patients with no clinical
data available, and children older than 21 years old, resulting in 2473 unique patients with
confirmed RV detection. Of those, 2382/2473 (96.3%) children had compatible symptoms
(RV symptoms group), and 91/2473 (3.7%) did not have symptoms compatible with RV
infection (RV incidental group). Within the cohort, 2099 children were hospitalized (85%),
and 374 (15%) were managed as outpatients.
The majority of children included in the RV symptoms group presented with a
respiratory-related diagnosis (2295/2382 (96.3%); Table 1). The most common respira-
tory diagnoses were upper respiratory tract infections (URTI), followed by bronchiolitis
and asthma exacerbations. The proportion of children with a lower respiratory tract in-
fection (LRTI)-related diagnosis (bronchiolitis, asthma, pneumonia; n = 1274) was higher
than those with URTI (n = 680; p < 0.001), with no differences in RV viral loads between
groups 25.02 (21.90–28.94) for URTI versus 25.28 (22.13–29.26) for LRTI-related diagnoses;
p = 0.245. Gastrointestinal (GI) symptoms (diarrhea, vomiting, dehydration, or decreased
oral intake) were present in 530/2382 (22.25%) patients, the majority in combination with
respiratory symptoms (460 with respiratory and GI symptoms; 70 (2.9%) with GI symptoms
exclusively). Fever with no other symptoms was the clinical presentation in 17/2382 (0.7%)
of children.
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Figure 1. Flow diagram depicting the selection of study patients. 
The majority of children included in the RV symptoms group presented with a res-
piratory-related diagnosis (2295/2382 (96.3%); Table 1). The most common respiratory di-
agnoses were upper respiratory tract infections (URTI), followed by bronchiolitis and 
asthma exacerbations. The proportion of children with a lower respiratory tract infection 
(LRTI)-related diagnosis (bronchiolitis, asthma, pneumonia; n = 1274) was higher than 
those with URTI (n = 680; p < 0.001), with no differences in RV viral loads between groups 
25.02 (21.90–28.94) for URTI versus 25.28 (22.13–29.26) for LRTI-related diagnoses; p = 
0.245. Gastrointestinal (GI) symptoms (diarrhea, vomiting, dehydration, or decreased oral 
intake) were present in 530/2382 (22.25%) patients, the majority in combination with res-
piratory symptoms (460 with respiratory and GI symptoms; 70 (2.9%) with GI symptoms 
exclusively). Fever with no other symptoms was the clinical presentation in 17/2382 (0.7%) 
of children. 
Table 1. Respiratory diagnosis in patients with compatible symptoms (n = 2295). 
Diagnosis N (%) 
URTI 680 (29.62) 
Bronchiolitis 483 (21.04) 
Asthma exacerbation 454 (19.80) 
Pneumonia 228 (9.93) 
LRTI 109 (4.74) 
Respiratory failure 160 (7.00) 
Apnea 5 (0.20) 
Hypoxemia 11 (0.47) 
CF exacerbation 46 (2.00) 
Ventilator-associated pneumonia 47 (2.04) 
AOM/sinusitis 26 (1.13) 
Airway malacia exacerbation 1 (0.04) 
Other 2 (0.09) 
Data presented as absolute numbers with percentages in parenthesis. Other included two children 
with an exacerbation of chronic pulmonary heart disease. URTI, upper respiratory tract infection; 
LRTI, lower respiratory tract infection; CF, cystic fibrosis; AOM, acute otitis media. 
Figure 1. Flow diagram depicting the selection of study patients.




Asthma exacerbation 454 (19.80)
Pneumonia 228 (9.93)
LRTI 109 (4.74)
Respiratory failure 160 (7.00)
Apnea 5 (0.20)
Hypoxemia 11 (0.47)
CF exacerbation 46 (2.00)
Ventilator-associated pneumonia 47 (2.04)
AOM/sinusitis 26 (1.13)
Airway malacia exacerbation 1 (0.04)
Other 2 (0.09)
Data presented as absolute numbers with percentages in parenthesis. Other included two children with an
exacerbation of chronic pulmonary heart disease. URTI, upper respiratory tract infection; LRTI, lower respiratory
tract infection; CF, cystic fibrosis; AOM, acute otitis media.
Children included in the RV incidental group had a variety of clinical presentations
(Table 2), including cardiovascul r manifestations, gastroesophageal reflux, Kawasaki
Disease, trauma, etc.
The seasonality of RV in hospitalized children over the 30-month (2011–2013) study
period is depicted in Figure 2. Of the 2099 hospitalized children with RV detection, 2048
had compatible symptoms and 51 were included in the RV incidental group. The number of
RV cases identified occurred steadily throughout the year, with over 100 patients per month
except for June and July. RV detection peaked in the last quarter of the year. Overall, most
of the cases were diagnosed in September 309/2099 (14.72%) without differences between
patients with compatible symptoms and those with RV incidental detection 303/2048
(14.79%) versus 6/51 (11.76%); p = 0.69. Similarly, there were no variations in seasonal
patterns in the rest of the year according to the clinical presentation.
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Neurological disorders 13 (14.28)
Immunocompromised 7 (7.70)
Kawasaki Disease 6 (6.59)
Seizures 5 (5.49)
Routine health examination 4 (4.40)
Hematologic disease 4 (4.40)
Syndromes 2 (2.20)
Sepsis/shock 2 (2.20)
Neuromuscular disorders 1 (1.10)




Data presented as frequency (percentage). GERD, gastroesophageal reflux disease.
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The horizontal axis shows the months of the year for RV detection in patients with
compatible (black) symptoms and RV incidental detection. The vertical axis shows the total
number of RV-associated hospitalizations in both groups.
3.2. Demographic Characteristics and Underlying Diseases
Demographic characteristics and underlying diseases in children with RV-associated
illnesses are summarized in Table 3. Overall, the median age was 14.3 (3.9–49) months
with no differences in age, sex, or race between children with RV-associated symptoms
and those with RV incidental detection. More than two-thirds of children in both groups
had underlying chronic conditions. Asthma/atopy/allergy were the most common un-
derlying conditions in children with compatible symptoms (42.15%) versus those with
incidental RV detection (18.31%; p = 0.012). On the other hand, congenital heart disease
was significantly more common in children with incidental RV detection than in those with
compatible symptoms (14.08% versus 4.40% respectively; p = 0.007). All children with CF
had compatible symptoms.
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(n = 91) p Value
Demographic
Characteristics
Age, (months) 14.35 (3.9–49.3) 14.10 (3.8–38.1) 0.844
Sex, n (%) male 1404 (58.94) 55 (60.44) 0.776
Race or ethnic group, n (%) 0.449
White 1320 (55.42) 58 (63.74)
Black or African American 641 (26.91) 19 (20.88)
Biracial 88 (7.89) 5 (5.49)
Other 233 (9.78) 9 (9.89)
Underlying diseases, n (%) 1886 (79.17) 71 (78.02) 0.031
Asthma/atopy/allergy 795 (42.15) 13 (18.31) 0.012
Genetic syndromes 256 (13.57) 18 (25.35) 0.096
Prematurity 251 (13.31) 9 (12.68) 0.774
Gastrointestinal diseases 82 (4.34) 4 (5.63) 0.734
Congenital heart disease 83 (4.40) 10 (14.08) 0.007
Neurological disorders 58 (3.08) 3 (4.23) 0.695
Cystic fibrosis 46 (2.44) 0 (0.00) -
Respiratory tract morbidity a 55 (2.92) 2 (2.82) 0.891
Immunodeficiencies 35 (1.86) 4 (5.63) 0.070
Hematologic disease 23 (1.22) 1 (1.41) 0.943
Other b 202 (10.71) 7 (9.86) 0.735
Continuous variables are expressed as medians 25–75% interquartile ranges (IQR) and categorical data as fre-
quency (%). Numbers in bold indicate significant p values. a Respiratory tract morbidity included neonatal
intubation for 10 or more days, in relation to meconium aspiration syndrome, gastroschisis, or congenital
diaphragmatic hernia. Other diseases included were tracheoesophageal fistula, pulmonary hypertension, sponta-
neous pneumothorax, airway malacia, subglottic stenosis, cleft palate, and Pierre–Robin sequence. b Endocrine,
ophthalmologic, osteoarticular, and genitourinary underlying diseases.
3.3. Viral and Bacterial Co-Infections
Rates and types of RV viral co-infections and results from bacterial cultures are
summarized in Table 4. Respiratory viral co-infections were more frequent in patients with
compatible symptoms than in children with incidental RV detection (22.3% versus 10.9%;
p = 0.010) with adenovirus being the most common viral pathogen co-detected in both
groups (9% and 10%, respectively). RSV and influenza A and B were co-detected in 7.7%
and 0.5% of children, respectively, and exclusively in children with compatible symptoms.
We also analyzed whether RV viral loads differed according to the clinical presentation
and co-detection of other respiratory viruses. We did not find significant differences in RV
loads in children with compatible symptoms versus those with incidental RV detection
(Table 4). In children with compatible symptoms, RV viral loads were significantly higher
(lower Ct values) than in children with RV mono-infections (n = 1850; 24.81 (21.53–25.88)
CT values) than in those with RV viral co-infections (n = 532; 26.85 (23.41–30.68) CT values;
p = 0.0001; Figure 3). These differences were not observed in children with incidental
RV detection in whom RV viral loads in RV mono-infections and co-infections were not
significantly different, i.e., (25.47 (22–29.07)) and (26.51 (23.9–27.3), respectively; p = 0.442).
Regarding bacterial cultures, children with compatible symptoms had significantly
lower rates of bacteremia (1.95% versus 7.69%, respectively; p = 0.015) and bacterial menin-
gitis (0.85% versus 7.7%, respectively; p = 0.028) than those in the RV incidental group. RV
viral loads in children with compatible symptoms and bacterial co-infections were compa-
rable to those without bacterial infections 24.9 (21.2–29.1) and 25.42 (22.04–29.3) CT values
respectively; p = 0.129). Similarly, children with RV incidental detection had comparable RV
viral loads irrespective of bacterial co-infections 26.21 (24.32–29.27) and 26.12 (21.66–30.25)
for children with and without bacterial co-infections respectively; p = 0.41).
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(n = 91) p Value
Viral co-infections a 532/2382 (22.33) 10/91(10.99) 0.010
Adenovirus 241 (10.12) 8 (8.79) 0.679
RSV 185 (7.77) 0 (0) 0.006
Parainfluenza 98 (4.12) 1 (1.10) 0.150
hMPV 53 (2.23) 2 (2.20) 0.986
Influenza A 9 (0.38) 0 (0) 0.557
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Bacterial co-infections b
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Cerebrospinal fluid culture 2/235 (0.85) 1/13 (7.69) 0.028
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Other cultures c 45/212 (21.23) 2/12 (16.67) 0.706
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Disease severity in children within the RV symptoms and RV incidental detection 
groups is summarized in Table 5. Overall, disease severity parameters were worst in chil-
dren with RV-associated symptoms than in those with RV incidental detection. The pro-
portion of hospitalized children in the RV symptoms group was higher than in the RV 
incidental cohort (85.98% versus 56.4%; p = 0.0001; OR, 95% CI: 4.8 (3.1–7.4)). In addition, 
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higher rates of PICU admission, and more frequent need for supplemental oxygen than 
children with incidental RV detection. Duration of supplemental oxygen via non-invasive 
or invasive mechanical ventilation was comparable between groups. 




(n = 2382) 
RV Incidental 
Group 





Hospitalization 2048 (85.98) 51 (56.4) 4.80 (3.12–7.39) 0.0001 
PICU 743 (31.19) 9 (9.89) 4.13 (2.06–8.26) 0.0001 
Length of stay a 2.4 (1.5–4.7) 1.7 (1–3.1)  1.90 (1.14–3.17) 0.013 
Length of stay in PICU b 2.4 (1.4–4.7) 1.6 (1.2–2.6)  3.30 (0.82–13.32) 0.093 
Suplemental oxygen     
Requirement, n (%) 1278 (53.65) 8 (8.79) 12.01(5.78–24.92) 0.0001 
Duration (days) c 2 (1–4) 2.5(1.5–6) 0.95 (0.19–4.74) 0.953 
Oxygen administration via     
Nasal Cannula 736 (57.59) 5 (62.50) 1.71 (0.40–7.24) 0.461 
NIV 285 (22.30) 0 (0) - - 
Mechanical ventilation 257 (20.11) 3 (37.50) 0.58 (0.13–2.45) 0.461 
Data presented as frequency (percentage). Numbers in bold indicate significant p values. a Pro-
longed hospital stay if greater than the median length of stay, which was 1.8 days. b Prolonged pe-
diatric intensive care unit (PICU) stay if greater than the median length of PICU stay, which was 1.9 
days. c Prolonged duration of supplemental oxygen if greater than median O2 supplementation that 
was 4 days. NIV, non-invasive ventilatory support; PICU, pediatric intensive care unit. 
ris f i l l i il r ti l s t s a -i f ti s
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3.4. Disease Severity Parameters in Children with Compatible Symptoms and Incidental RV Detection
Disease severity in children within the RV ymptoms and RV inci ental detection
groups is summarized in Tabl 5. Overall, disease severity parameters w re wo st in
children with RV-associated symptoms than in those with RV incidental detection. Th
proportion of hospitalized children in the RV symptoms group was higher than in the RV
incidental cohort (85.98% versus 56.4%; p = 0.0001; OR, 95% CI: 4.8 (3.1–7.4)). In addition,
childr n with compatible ymptoms had more prolonged duration of hospitalizations,
higher rates of PICU admission, and m re frequent need for supplem ntal oxygen than
children with incidental RV detection. Duration of supplemental oxygen via non-invasive
or invasiv mechanic l ventilation was comparable between gr ups.
Lastly, we performed multivariable logistic regression analyses to determine whether
symptomatic or incidental RV detection was associated with the outcomes of care identified
as significantly different in bivariate analyses, namely, need for hospitalization, need for
supplemental oxygen, PICU admission, and length of stay, which was dichotomized by the
median in ≤1.8 days and >1.8 days. We included as covariates in the models’ demographic
factors, RV viral loads, viral co-infections, and presence of comorbidities (Table 6).
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stay if greater than the median length of PICU stay, which was 1.9 days. c Prolonged duration of supplemental
oxygen if greater than median O2 supplementation that was 4 days. NIV, non-invasive ventilatory support; PICU,
pediatric intensive care unit.













Age 1.06 (1.03–1.09) 0.0001 1.07 (1.05–1.09) 0.0001 1.10 (1.08–1.13) 0.0001 1.08 (1.06–1.10) 0.0001
Female 0.90 (0.72–1.13) 0.386 0.96 (0.80–1.14) 0.662 0.98 (0.82–1.17) 0.838 0.94 (0.80–1.11) 0.494
RV viral loads 0.99 (0.97–1.01) 0.319 0.97 (0.95–0.99) 0.004 0.98 (0.96–1.00) 0.090 0.99 (0.97–1.00) 0.087
RV viral co-infections a 0.73 (0.57–0.95) 0.021 1.2 (0.96–1.4) 0.094 1.04 (0.84–1.29) 0.682 1.11 (0.91–1.35) 0.314
Compatible symptoms 4.99 (3.23–7.73) 0.0001 3.9 (1.95–7.92) 0.0001 2.03 (1.20–3.42) 0.008 11.86 (5.68–24.76) 0.0001
Underlying diseases 1.01 (0.98–1.04) 0.650 0.98 (0.96–1.00) 0.121 1.02 (1.00–1.04) 0.030 0.98 (0.96–1.00) 0.059
Odds ratios (ORs) and 95% confidence interval (CI). Numbers in bold indicate significant p values. a Viral co-infection indicates the
detection of more than one respiratory virus apart from RV: respiratory syncytial virus (RSV), parainfluenza virus, influenza virus A and B,
adenovirus, or hMPV.
Age and presence of RV-associated symptoms were consistently and independently
associated with all outcomes of care. In addition, higher viral loads (lower Ct values)
increased the risk of PICU admission while viral co-infections were associated with de-
creased odds of hospitalization. Underlying diseases increased the odds of longer length
of stay adjusted for all other covariates.
4. Discussion
In the present study, we analyzed the differences in demographic factors, microbiology,
and clinical outcomes in children with classic RV-associated symptoms and those with
incidental RV detection. We found that irrespective of their clinical presentation, a high
proportion of children had underlying chronic medical conditions, with asthma being
more prevalent in children with RV-compatible symptoms. While we did not find any
differences in RV viral loads according to their clinical presentation, RV loads in children
with compatible symptoms and single RV detection were significantly higher than in those
with RV viral co-infections. On the other hand, severe bacterial infections (SBI) defined as
bacteremia and meningitis were more frequent in children with RV incidental detection
than with classic RV-associated illnesses. Overall, this study illustrates the relevant role of
RV associated illnesses beyond asthma and the importance of combining demographic and
clinical information to facilitate the interpretation of RV detection in the clinical setting.
To define the role of RV in clinical disease severity, different studies have either
compared clinical outcomes in children with RV infections versus infections with other
respiratory viruses [22], or whether differences in severity exist according to RV geno-
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types [3,7,16,17,23–28]. In addition, the high prevalence of RV detection has stimulated
investigators to address the role of RV in asymptomatic subjects [10,13,29] and also in
patients hospitalized with respiratory symptoms [27]. In the present study, we consid-
ered a broader approach and focused our efforts on understanding the significance of RV
detection in a large cohort of children with a wide variety of clinical presentations. We
analyzed whether differences existed in demographic parameters, virology characteristics,
and clinical disease severity in both outpatients and inpatients with and without classic
RV-associated illnesses.
The classic clinical presentations associated with RV infections include URTI, bronchi-
olitis, and asthma exacerbations being the most common, followed by tracheitis, laryngitis,
otitis media, or fever [1,3,4,14,30,31]. In the present study, in addition to asthma, which was
the most common diagnosis, we identified a large proportion of children with involvement
of the lower respiratory tract, with diagnoses of bronchiolitis, pneumonia, and LRTI. To-
gether as a group, these children represented 37% of all those in the RV compatible illness
group. Studies have also identified RV in stool samples from patients with gastrointestinal
syndromes [32], suggesting it may play a role in their clinical presentation [27]. In addition,
decreased oral intake was identified as a relevant GI symptom of RV associated illnesses
at all ages [16–19]. For these reasons and although the majority of children with GI mani-
festations in our cohort also had respiratory symptoms, children with GI symptoms were
included in the group of children with compatible RV symptoms.
In agreement with previous studies, the prevalence of underlying chronic conditions
in children with RV detection was high and independently associated with worse clinical
outcomes, suggesting their higher vulnerability to severe RV infections [2,16,19,28]. Of
those pre-existing conditions, and as reported by several previous studies, asthma was the
most prevalent underlying disease identified both in children with classic RV-associated
illnesses and in those with incidental RV detection [8,13,25,27,33,34]. In agreement with
previous studies, we identified RV in children with CF exacerbations [4,8,31,35]. In fact,
RV was associated with an earlier decline in lung function in patients with CF [8]. We also
found that non-pulmonary diseases were commonly present in children with incidental
RV detection, such as congenital heart diseases, which may indicate the inability of these
patients to properly clear RV from the respiratory tract [2]. However, it may also reflect
a clinical decision for enhancement of testing in this high-risk population. Prematurity
has also been identified as a risk factor for severe RV respiratory infections, including
community-acquired pneumonia, and was present in 13% of children in our study [6,18,36].
Immunocompromised patients are at a greater risk of severe RV infections [8,37]. On the
other hand, incidental detection of RV in these patients has been reported. In agreement
with previous studies, rates of RV detection in immunocompromised children without the
classic RV-associated symptoms was not uncommon [38].
Rates of RV co-infections with other respiratory viruses were more common in children
with compatible symptoms. In line with prior studies, RSV was one of the most frequent
virus co-detected in patients with RV-associated respiratory illnesses [2,7,19,25], but not
in those with incidental RV detection [24,33]. On the other hand, adenovirus was the
most common co-pathogen identified in both children with compatible symptoms and
in children with incidental RV detection [16,26]. The number of children with influenza
co-detections was low and similar to other reports [16,25], suggesting the possibility of an
interference mechanism [16,19].
Most of the studies that have evaluated the role of RV viral loads in RV-associated
illnesses found higher viral loads in symptomatic than in asymptomatic patients [10–14]. In
our study, children included in the incidental detection group, rather than asymptomatic,
were hospitalized with diseases not presenting with the classic RV-associated symptoms,
which may explain the differences observed between our study and previous reports.
Investigators have also attempted to define the role of RV viral loads and/or identify viral
load cut-offs predictive of clinical disease severity with different results [10,12–14,27,39,40].
While higher RV loads were associated with higher clinical disease severity scores, increased
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risk of LRTI, and respiratory failure in children [27,40,41], other studies have not confirmed
these associations [39,42], which may be explained by differences in study design and
patients populations included.
Overall, bacterial co-infections in children with RV infections are low, although rates
may vary according to the clinical presentation [7,16,43,44]. Higher rates of SBI were
reported in patients with LRTI requiring PICU care [45] and in the young infant with
fever without a source, in whom RV detection is not associated with a decreased risk of
SBI, such as urinary tract infections and bacteremia [46]. In our study, the median age of
study subjects was 14 months, and rates of bacterial co-infections were higher in patients
with incidental RV detection, further suggesting that the bacterial pathogens identified in
patients with SBI were responsible for the clinical presentation and RV detection a true
incidental finding.
Different clinical outcomes, such as the need for supplemental oxygen, PICU care,
length of hospital stay, or need for mechanical ventilation have been used to assess the
severity of RV-associated illnesses in children [5,16,18,22–26]. In our study, we found that
children presenting with RV illnesses and compatible symptoms had consistently greater
disease severity, as assessed by the outcomes of care mentioned above and adjusted for all
other covariates, highlighting the increased risk of enhanced disease in these children.
Our study has limitations. Its retrospective design limited our ability to collect precise
information related to factors, such as a family history of asthma or second-hand smoke ex-
posure that may have influenced the clinical outcomes assessed. In addition, host immune
responses were not assessed and thus the contribution of RV to the illnesses identified could
not be fully elucidated. Duration of illness at the time of sample collection might have
influenced RV viral loads, but this parameter was not collected. Despite this limitation,
we found that children with compatible symptoms and RV mono-infections had higher
RV viral loads than those with RV viral co-infections. Lastly, the study was performed
at a single center, and over a limited duration, and the convenience sample of patients
tested might represent the subset of patients with more severe disease. Nevertheless, NCH
is the only pediatric hospital in central Ohio and serves a large and varied population
of pediatric patients, which allowed us to conduct multivariable analyses adjusted for
these confounders.
In conclusion, this study represents one of the largest case series to date describing the
spectrum of RV associated illnesses in children, further comparing children with common
symptoms with those with RV incidental detection. While incidental detection of RV in
patients with non-compatible symptoms was low, children with classic RV illnesses had
worse disease severity assessed by different outcomes of care analyzed. RV viral loads were
comparable in children with classic RV symptoms and those with RV incidental detection.
Whether RV played a role in the clinical presentation of these children irrespective of their
clinical classification deserves further studies linking RV detection and viral loads with
host immune responses. In summary, we found that a detailed classification of pediatric
patients with RV detection based on clinical presentations, viral loads, and rates of viral
and bacterial co-infections shed light on the different RV clinical phenotypes and may help
with patient classification in the clinical setting.
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